ForeSee Medical and Vim Announce Strategic Partnership to Enhance Risk Adjustment and Streamline Provider Workflows
SAN DIEGO--(BUSINESS WIRE)--ForeSee Medical Inc., a leading AI-powered risk adjustment software company, and Vim, a cutting-edge provider enablement platform for healthcare, have announced a strategic partnership aimed at transforming the delivery of patient insights and improving provider workflows at the point of care.
'We are excited to partner with Vim to bring our industry-leading, AI-powered risk adjustment capabilities directly into provider workflows,' said Dr. Sol Lizerbram, Executive Chairman at ForeSee Medical.
Through this collaboration, ForeSee Medical's advanced risk adjustment technology, which assists providers in accurately identifying Hierarchical Condition Categories (HCC) coding while improving the quality of care, will seamlessly integrate into Vim's scalable and flexible platform. By leveraging Vim's unique and interactive integration layer, providers will gain access to enhanced data and patient insights directly within their Electronic Health Record (EHR) workflows—without disrupting existing clinical operations.
'We are excited to partner with Vim to bring our industry-leading, AI-powered risk adjustment capabilities directly into provider workflows,' said Dr. Sol Lizerbram, Executive Chairman at ForeSee Medical. 'This partnership ensures that providers can access accurate risk adjustment data in real time, ultimately leading to improved patient care and clinical outcomes. Our proprietary Natural Language Processing (NLP) along with unique features such as InstaVu®' greatly reduces the speed to achieve accurate HCC coding with the ability to instantly view disease source documentation.'
Vim's provider enablement platform is designed to bridge gaps in interoperability and efficiency, enabling health organizations to enhance operational effectiveness. With ForeSee Medical's technology integrated into Vim's workflow solutions, healthcare providers will experience a streamlined approach to risk adjustment coding, reducing administrative burden and improving decision-making at the point of care.
'Our partnership with ForeSee Medical brings together two powerful capabilities—real-time data delivery and AI-driven risk insights—into one seamless experience for providers. At Vim, we're focused on turning fragmented healthcare data into actionable intelligence directly within clinical workflows,' said Tim Barry, Head of Partnerships at Vim. 'This collaboration is another step in our mission to power smarter, faster decisions at the point of care—without adding complexity.'
This partnership represents a significant step forward in healthcare technology, ensuring that providers can leverage AI-driven insights effortlessly within their daily operations, leading to greater accuracy, efficiency, and overall quality of care.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
25 minutes ago
- Business Wire
Somnics Health Launches iNAP Essentials: Making Innovative OSA Therapy Accessible for $58/Month
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Somnics Health, a pioneer in next-generation sleep apnea solutions, announces the launch of iNAP Essentials, a breakthrough program giving patients access to iNAP Sleep Therapy for just $58/month over 24 months. This new initiative removes one of the biggest barriers to treatment—cost—and expands access to comfortable, mask-free therapy for patients with Obstructive Sleep Apnea (OSA). Sleep apnea is a serious condition, and we believe everyone deserves a shot at better health. We're making it now effective and affordable to many patients in the US. No need for insurance! Share More than 50 million Americans suffer from OSA, yet 80% remain untreated, and many who start CPAP therapy abandon it due to discomfort. The iNAP system offers a new path forward. 'The OSA treatment landscape is no longer CPAP-only. iNAP is effective, comfortable, and discreet—and now, more affordable than ever,' said Olivier Lauzeral, General Manager of Somnics Health. 'With iNAP Essentials, we're removing the affordability hurdle.' A Smarter, Simpler Solution iNAP is an FDA-cleared, clinically validated therapy that uses gentle negative pressure to keep the airway open during sleep—without forcing air through a mask. It works by creating a light vacuum in the oral cavity, shifting soft tissues forward and preventing obstruction. Key benefits include: No mask, no noise, no forced air Compact and travel-friendly Rechargeable battery lasting up to 5 nights Patients appreciate the freedom and discretion the iNAP system offers, particularly for travel and daily life. 'Adherence is one of iNAP's biggest strengths,' added Lauzeral. 'When therapy fits into your life instead of disrupting it, patients stay with it—and that's how we win against OSA.' What's Included in iNAP Essentials For $58/month for 24 months, iNAP Essentials includes: A full iNAP Starter Kit 3 months of supplies (mouthpiece, tubing) Free nationwide shipping Personalized onboarding with a trained iNAP Sleep Coach Access to the iNAP Sleep App for tracking progress and sharing data with providers After the initial supply period, patients can purchase refills as needed from Somnics' online store—offering flexibility without hidden fees or long-term commitments. 'We built this program with transparency and simplicity at its core,' said Lauzeral. 'It's everything you need to start treatment—nothing you don't.' Addressing a Changing Market While CPAP has long dominated the OSA space, patient dissatisfaction is driving demand for alternatives like oral appliances, positional therapy, and implantable devices. Many of these, however, are costly, invasive, or hard to access. iNAP stands out as non-invasive, portable, and now financially accessible. Clinical studies show iNAP can significantly reduce AHI, with outcomes on par with CPAP—but with higher comfort and adherence. More Ways to Access iNAP For patients who prefer to own their device upfront, Somnics has partnered with Affirm® to offer interest-free installment plans. 'Some patients want to purchase the device outright. With Affirm, they can do that without financial strain,' said Lauzeral. Provider-Guided, Patient-Focused iNAP is available by prescription only, ensuring medical oversight from a sleep specialist. Adoption is growing across VA hospitals, sleep centers, and DME providers. 'Physicians are seeing the value of iNAP in improving adherence and patient satisfaction,' Lauzeral emphasized. 'When patients feel empowered, they stay engaged—and that's the future of sleep medicine.' Advancing Health Equity Untreated sleep apnea increases the risk of heart disease, stroke, diabetes, and cognitive decline. Somnics Health sees iNAP Essentials not just as a product offering—but as a public health solution. 'This isn't just about access—it's about fairness,' said Lauzeral. 'Sleep apnea is a serious condition, and we believe everyone deserves a shot at better health.' About Somnics Health Somnics Health is a medical device company focused on advancing patient-centric solutions for sleep-disordered breathing. Its flagship product, iNAP Sleep Therapy, helps patients treat OSA without the discomfort of traditional therapies. With offices in California and Taiwan, Somnics continues to lead in innovation, education, and patient adherence.
Yahoo
25 minutes ago
- Yahoo
IFF Appoints Virginia "Gina" Drosos to Board of Directors
NEW YORK, June 09, 2025--(BUSINESS WIRE)--IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. "We are very pleased to welcome Gina to the IFF board," said Kevin O'Byrne, chair of the board. "Gina brings extensive relevant experience, deep consumer insights and a proven ability to drive innovation and lead with purpose, which aligns with our long-term strategy to deliver sustainable growth and value creation for all stakeholders." Drosos most recently served as chief executive officer and a director of Signet Jewelers Ltd. (NYSE: SIG)—the world's largest retailer of diamond jewelry—from August 2017 to November 2024. During her tenure, she led the company through a significant transformation, expanding its digital capabilities and enhancing customer experience. Gina also spent 25 years at Procter & Gamble (NYSE: PG)—most recently as group president of global beauty, skin, cosmetics and personal care—where she established herself as a transformative, purpose-led leader who drove game-changing innovation, built multi-billion-dollar brands and reinvented global categories. She currently serves as a director of Foot Locker Inc. and the United States Golf Association and previously served as a board member of American Financial Group, Inc., where she served on the audit and governance committees. "I'm honored to join the IFF board at such a pivotal time in the company's journey," said Drosos. "IFF's commitment to innovation, sustainability and purpose-driven growth deeply resonates with me. I look forward to contributing to the company's long-term strategy and helping shape its future as a global leader in food and beverage, home and personal care and health and wellness solutions." Cautionary Statement under the Private Securities Litigation Reform Act of 1995 This press release contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as ""plan", "expect," "anticipate," "intend," "believe," "seek," "see," "will," "would," "target," similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the timing or nature of the new facilities. The forward-looking statements included in this release are made only as of the date hereof, and we undertake no obligation to update the forward-looking statement to reflect subsequent events or circumstances. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on Contacts Media Relations:Paulina Investor Relations:Michael Sign in to access your portfolio
Business Wire
30 minutes ago
- Business Wire
IFF Appoints Virginia 'Gina' Drosos to Board of Directors
NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. 'We are very pleased to welcome Gina to the IFF board,' said Kevin O'Byrne, chair of the board. 'Gina brings extensive relevant experience, deep consumer insights and a proven ability to drive innovation and lead with purpose, which aligns with our long-term strategy to deliver sustainable growth and value creation for all stakeholders.' Drosos most recently served as chief executive officer and a director of Signet Jewelers Ltd. (NYSE: SIG)—the world's largest retailer of diamond jewelry—from August 2017 to November 2024. During her tenure, she led the company through a significant transformation, expanding its digital capabilities and enhancing customer experience. Gina also spent 25 years at Procter & Gamble (NYSE: PG)—most recently as group president of global beauty, skin, cosmetics and personal care—where she established herself as a transformative, purpose-led leader who drove game-changing innovation, built multi-billion-dollar brands and reinvented global categories. She currently serves as a director of Foot Locker Inc. and the United States Golf Association and previously served as a board member of American Financial Group, Inc., where she served on the audit and governance committees. 'I'm honored to join the IFF board at such a pivotal time in the company's journey,' said Drosos. 'IFF's commitment to innovation, sustainability and purpose-driven growth deeply resonates with me. I look forward to contributing to the company's long-term strategy and helping shape its future as a global leader in food and beverage, home and personal care and health and wellness solutions.' Cautionary Statement under the Private Securities Litigation Reform Act of 1995 This press release contains 'forward-looking statements' within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). Forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as ''plan', 'expect,' 'anticipate,' 'intend,' 'believe,' 'seek,' 'see,' 'will,' 'would,' 'target,' similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the timing or nature of the new facilities. The forward-looking statements included in this release are made only as of the date hereof, and we undertake no obligation to update the forward-looking statement to reflect subsequent events or circumstances. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
